Introduction to the Metabolic Crisis in South Asia

Non-communicable diseases currently account for over 70% of global mortality, with metabolic risk factors serving as the primary drivers of this epidemic. In the South Asian context, the prevalence of conditions like obesity, dyslipidemia, and hypertension has surged due to rapid lifestyle transitions. Consequently, healthcare providers in India and neighboring regions face a unique challenge: the "thin-fat" phenotype. This clinical presentation involves high visceral adiposity despite a relatively low body mass index. Therefore, identifying the underlying molecular and genetic mechanisms is essential for developing effective prevention strategies. Recent research focuses on FGF1 and metabolic risk to better understand these pathways. By examining specific biomarkers and genetic variations, clinicians can pinpoint individuals at the highest risk for cardiovascular and endocrine complications. Understanding these drivers is particularly vital as South Asians often develop metabolic dysfunction at a younger age compared to other ethnic groups. Thus, integrating genetic insights with clinical practice could revolutionize how we manage chronic metabolic conditions in this specific demographic.

The Biological Role of Fibroblast Growth Factor 1

Fibroblast Growth Factor 1, commonly referred to as FGF1, plays a critical role in nutrient sensing and metabolic homeostasis. Essentially, this hormone acts as a regulator of adipose tissue remodeling and insulin sensitivity. When the body enters a state of nutrient excess, FGF1 signaling helps the adipose tissue expand healthily, preventing the overflow of lipids into non-adipose organs like the liver and heart. However, when this system becomes dysregulated, it contributes significantly to the development of insulin resistance and chronic inflammation. Specifically, serum levels of FGF1 often correlate with various metabolic parameters, including blood pressure and lipid profiles. Researchers have noted that higher circulating levels might reflect a compensatory mechanism in response to metabolic stress. Furthermore, FGF1 influences glucose metabolism by enhancing insulin action without the risk of hypoglycemia. This unique attribute makes it a focus of intense therapeutic interest for managing type 2 diabetes. By stabilizing metabolic flux, FGF1 helps maintain systemic health, making its study indispensable for addressing the root causes of metabolic syndrome in susceptible populations.

Genetic Insights: The rs152524 Polymorphism

Genetic susceptibility plays a major role in how individuals respond to environmental triggers of metabolic disease. Among the various genetic variants, the rs152524 polymorphism in the FGF1 gene has emerged as a significant factor. Specifically, this single nucleotide polymorphism can influence the expression levels of FGF1, thereby altering an individual’s metabolic profile. Recent studies utilizing advanced techniques like tetra-primer ARMS PCR have successfully genotyped this variant in South Asian cohorts. The distribution of genotypes—CC, CT, and TT—reveals how different alleles contribute to the risk of obesity and hypertension. Notably, the presence of certain risk alleles is strongly associated with elevated serum FGF1 and worsened metabolic markers. This genetic link suggests that some patients are predisposed to metabolic syndrome regardless of lifestyle factors alone. Consequently, identifying the rs152524 status could potentially serve as a predictive tool in clinical settings. Such personalized data allow for more targeted interventions, ensuring that high-risk individuals receive aggressive management earlier in their disease progression. This genetic approach bridges the gap between general epidemiology and individualized patient care.

Gender-Specific Patterns in Metabolic Profiles

A striking finding in recent metabolic research is the significant disparity in how risk factors manifest between genders. In the South Asian population, females often exhibit a higher prevalence of metabolic syndrome compared to their male counterparts. Specifically, the relationship between FGF1 and metabolic risk appears much more pronounced in women. Clinical data indicate that women often show higher correlations between serum FGF1 levels and metrics like waist circumference or diastolic blood pressure. Furthermore, the rs152524 gene polymorphism shows a substantial association with metabolic risk factors notably in females. This gender-wise distribution might be attributed to hormonal differences or variations in adipose tissue distribution. While males frequently present with earlier cardiovascular symptoms, females may harbor a more complex metabolic profile that includes higher levels of dyslipidemia and central obesity. Recognizing these gender-specific nuances is vital for Indian physicians when screening for NCDs. Tailoring diagnostic thresholds and treatment plans to account for these biological differences can significantly improve outcomes. Therefore, gender must be a primary consideration in any comprehensive metabolic assessment.

Clinical Implications for South Asian Patients

The high burden of heart disease and diabetes in India necessitates a deeper look at regional metabolic data. Since South Asians bear nearly 60% of the global heart disease burden, clinical strategies must evolve. The association between FGF1 levels and metabolic markers provides a potential biomarker for early detection of systemic dysfunction. For instance, an elevated FGF1 level in a patient with borderline hypertension might signal an underlying genetic predisposition to metabolic collapse. Moreover, understanding the rs152524 variant helps explain why some patients remain resistant to standard lifestyle modifications. Clinically, this means that a one-size-fits-all approach is no longer sufficient. Instead, physicians should consider a more holistic view that includes genetic risk, gender, and regional phenotypic characteristics. Encouraging regular screening of lipid profiles and blood pressure in individuals with a family history of NCDs remains a cornerstone of preventive medicine. Additionally, focusing on early-life nutrition and activity can mitigate some of the genetic risks identified in these studies. Ultimately, the goal is to reduce the incidence of catastrophic cardiovascular events through precise and timely intervention.

Future Directions in Personalized Metabolic Medicine

As we move toward a more personalized era of medicine, the integration of genomics into routine practice becomes increasingly likely. Future research will likely explore how FGF1-targeted therapies can be used to treat insulin resistance and obesity directly. Currently, clinical trials are examining the safety and efficacy of FGF1 analogs in human subjects. These advancements could provide a new avenue for patients who do not respond well to traditional oral hypoglycemics or statins. Furthermore, combining genetic testing for polymorphisms like rs152524 with traditional risk scores could enhance the accuracy of cardiovascular risk prediction models. Healthcare systems must also focus on educating patients about their unique genetic risks to foster better adherence to treatment. In the Indian context, where resources are often stretched, prioritizing high-risk individuals based on genetic and biomarker data can improve the efficiency of public health programs. The ongoing study of FGF1 and metabolic risk represents just the beginning of this shift. Continued investment in local research is essential to ensure that South Asian populations benefit from the latest scientific breakthroughs in metabolic health.

Frequently Asked Questions

How does the rs152524 gene polymorphism affect metabolic health?

The rs152524 polymorphism is a variation in the FGF1 gene that influences how the body expresses this critical metabolic hormone. Specifically, individuals carrying certain alleles may experience altered FGF1 production, which impacts how they store fat and respond to insulin. In South Asian populations, this genetic variant is linked to a higher risk of developing obesity and hypertension, particularly in women. Understanding your genetic profile can help doctors personalize your prevention strategy.

Why is FGF1 considered a promising biomarker for metabolic syndrome?

FGF1 serves as a nutrient sensor and a regulator of insulin sensitivity and adipose tissue health. Unlike many other factors, it can enhance insulin action without causing dangerously low blood sugar levels. Because its circulating levels change in response to metabolic stress and fat accumulation, it acts as a measurable indicator of systemic metabolic health. Elevated levels often reflect the body’s attempt to compensate for underlying issues like chronic inflammation or lipid imbalance.

Are South Asian women at a higher risk for these metabolic complications?

Research suggests that South Asian women show a more significant association between genetic variants and metabolic risk factors compared to men. This often manifests as higher rates of central obesity and dyslipidemia, even at lower body weights. Factors such as the rs152524 polymorphism and fluctuations in FGF1 levels are more closely tied to hypertension and obesity in females. Consequently, targeted screening and early intervention are crucial for managing heart health in this demographic.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Mohsin SN et al. Gender-wise distribution of metabolic risk factors and their relationship with fibroblast growth factor 1 and gene polymorphism (rs152524). BMC Med Genomics. 2026 Jul 14. doi: 10.1186/s12920-026-02427-1. PMID: 42443887.

Kanaya A et al. The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study: Understanding Metabolic Disease Patterns. J Am Heart Assoc. 2024. doi: 10.1161/JAHA.123.031000.

Bu T et al. FGF1 as a New Promising Therapeutic Target in Type 2 Diabetes: Advances in Research and Clinical Trials. Diabetes Metab Syndr Obes. 2025;18:1137-1149. doi: 10.2147/DMSO.S505285.